Evidence for the release of 1-methyl-4-phenylpyridinium (MPP+) from rat striatal neurons in vitro.
[3H]MPP+ (1-[methyl-3H]4-phenylpyridinium) is taken up into rat striatal slices in a temperature-, time- and Na+-dependent process blocked by dopamine (DA) uptake inhibitors. Once taken up, authentic [3H]MPP+ is released at 37 degrees C by 15 mM KCl. This release is inhibited by (-)N-propyl-norapomorphine and enhanced by (-)sulpiride, as observed under the same conditions for [3H]DA release. Thus, rat striatal DA-ergic nerve endings do not discriminate between DA and MPP+ for their active transport and DA autoreceptor-regulated release.
D015655:1-Methyl-4-phenylpyridinium; D000818:Animals; D001058:Apomorphine / Q000031:analogs & derivatives / Q000494:pharmacology; D003342:Corpus Striatum / Q000378:metabolism*; D004298:Dopamine / Q000032:analysis / Q000378:metabolism*; D018492:Dopamine Antagonists; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011726:Pyridinium Compounds / Q000378:metabolism* / Q000494:pharmacology; D051381:Rats; D013469:Sulpiride / Q000494:pharmacology; D013696:Temperature; D013997:Time Factors
D018492:Dopamine Antagonists; D007546:Isoquinolines; D010879:Piperazines; D011726:Pyridinium Compounds; C031292:diclofensine; C047990:1-(2-(diphenyloxy)ethyl)-4-(3-phenylallyl)piperazine; C009074:N-n-propylnorapomorphine; D011189:Potassium Chloride; D013469:Sulpiride; D001058:Apomorphine; D015655:1-Methyl-4-phenylpyridinium; D004298:Dopamine